Last reviewed · How we verify
Placebo/Valdecoxib
Placebo/Valdecoxib is a Selective COX-2 inhibitor (coxib) Small molecule drug developed by Pfizer. It is currently in Phase 3 development for Acute pain, Rheumatoid arthritis, Osteoarthritis.
Valdecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain.
Valdecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain. Used for Acute pain, Rheumatoid arthritis, Osteoarthritis.
At a glance
| Generic name | Placebo/Valdecoxib |
|---|---|
| Sponsor | Pfizer |
| Drug class | Selective COX-2 inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Valdecoxib is a selective COX-2 inhibitor that preferentially blocks the inducible cyclooxygenase-2 enzyme while sparing COX-1, thereby reducing inflammatory prostaglandins while theoretically preserving gastroprotective prostaglandins. This selective inhibition provides anti-inflammatory and analgesic effects with potentially fewer gastrointestinal side effects compared to non-selective NSAIDs.
Approved indications
- Acute pain
- Rheumatoid arthritis
- Osteoarthritis
Common side effects
- Cardiovascular events (myocardial infarction, stroke)
- Gastrointestinal ulceration
- Hypertension
- Edema
- Dyspepsia
Key clinical trials
- Effect of Intravenous Dynastat on Postoperative Sore Throat (PHASE2)
- A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan) (PHASE2)
- Analgesic Efficacy Of Valdecoxib In Patients Following Bunion Surgery (PHASE3)
- A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED) (PHASE3)
- A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED) (PHASE3)
- Valdecoxib in Treating Chronic Pain in Cancer Patients (NA)
- A Study of the Recovery Benefits After Treatment With Parecoxib/Valdecoxib in Patients Undergoing Abdominal Surgery (PHASE3)
- A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo/Valdecoxib CI brief — competitive landscape report
- Placebo/Valdecoxib updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Placebo/Valdecoxib
What is Placebo/Valdecoxib?
How does Placebo/Valdecoxib work?
What is Placebo/Valdecoxib used for?
Who makes Placebo/Valdecoxib?
What drug class is Placebo/Valdecoxib in?
What development phase is Placebo/Valdecoxib in?
What are the side effects of Placebo/Valdecoxib?
What does Placebo/Valdecoxib target?
Related
- Drug class: All Selective COX-2 inhibitor (coxib) drugs
- Target: All drugs targeting COX-2 (Cyclooxygenase-2)
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Pain Management / Rheumatology
- Indication: Drugs for Acute pain
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Osteoarthritis
- Compare: Placebo/Valdecoxib vs similar drugs
- Pricing: Placebo/Valdecoxib cost, discount & access